{"id":692831,"date":"2022-10-06T08:29:25","date_gmt":"2022-10-06T12:29:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/"},"modified":"2022-10-06T08:29:25","modified_gmt":"2022-10-06T12:29:25","slug":"unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/","title":{"rendered":"UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>-Webinar to feature presentation from retinal expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 at 5:00 a.m. PT\/8:00 a.m. ET-<\/em><br \/>\n        \n      <\/p>\n<p>SOUTH SAN FRANCISCO, Calif., Oct.  06, 2022  (GLOBE NEWSWIRE) &#8212; UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an Investor\/Analyst Day on Wednesday, October 12, 2022 at 5:00 a.m. PT\/8:00 a.m. ET to discuss the current treatment landscape and unmet medical need for age-related diseases of the eye, and the potential treatment solution that UNITY\u2019s lead program, UBX1325, may provide.<\/p>\n<p>Members of UNITY\u2019s senior management team and Key Opinion Leader Robert B. Bhisitkul, M.D., Ph.D., (University of California San Francisco School of Medicine) will discuss the proposed mechanism of action of UBX1325 and new preclinical data that supports the senolytic approach in retinal diseases, the most recent UBX1325 clinical data from the BEHOLD study in Diabetic Macular Edema (DME), the ENVISION study in wet Age-related Macular Degeneration (wet AMD), including details of the new 48-week long-term follow-up extension study and near-term value driving milestones.<\/p>\n<p>The live webcast can be accessed in the \u201cInvestors and Media\u201d section of our website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iz2a7e-pzlMQ1nKSbt94VwlgXZMmWka7tse2vxD8ChIzfbt0NTapqQ1N6qZl7nBqX2FkE-nhV6yikaP2TViGkSWAB8u_UHoMr6EzaNRpLHo3ZIpzhhPtvTF5Y4S5cGUQ\" rel=\"nofollow noopener\" target=\"_blank\">www.unitybiotechnology.com<\/a>, under \u201cEvents &amp; Presentations\u201d or by clicking <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PVmFv7MHN_ZfKv_AUrLRepiY05q9mr-sP9JC0pnDeIIIbxM6gxJwyaNtbNlXeNA42I6phtWPK3wm15zbY0_nDWKi-qBK5w7ZHUHVFaagX_K6QM-C3lSPm3vy9y4L_7XatNNPnXglHu86pP0ekO2_uA==\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>. A replay will be available two hours after the completion of the call and can be accessed in the \u201cInvestors &amp; Media\u201d section of our website, under \u201cEvents and Presentations.\u201d<\/p>\n<p>\n        <strong>About UNITY<\/strong><br \/>\n        <br \/>UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY\u2019s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.<\/p>\n<p>Source: Unity Biotechnology, Inc<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTkzMyM1MTkwMTcxIzIwOTgyMjk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzNmYmI0MTItNTAyNS00YzNhLWE2MzQtZTJkNDYzYzljZGIwLTExMDk4MDA=\/tiny\/Unity-Biotechnology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Media Contact:\r\nCanale Communications\r\nJason Spark\r\njason.spark@canalecomm.com\r\n\r\nInvestor Contact:\r\nJoyce Allaire\r\nLifeSci Advisors\r\n212-915-2569\r\njallaire@lifesciadvisors.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>-Webinar to feature presentation from retinal expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 at 5:00 a.m. PT\/8:00 a.m. ET- SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an Investor\/Analyst Day on Wednesday, October 12, 2022 at 5:00 a.m. PT\/8:00 a.m. ET to discuss the current treatment landscape and unmet medical need for age-related diseases of the eye, and the potential treatment solution that UNITY\u2019s lead program, UBX1325, may provide. Members of UNITY\u2019s senior management team and Key Opinion Leader Robert B. Bhisitkul, M.D., Ph.D., (University of California San Francisco School of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692831","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"-Webinar to feature presentation from retinal expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 at 5:00 a.m. PT\/8:00 a.m. ET- SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an Investor\/Analyst Day on Wednesday, October 12, 2022 at 5:00 a.m. PT\/8:00 a.m. ET to discuss the current treatment landscape and unmet medical need for age-related diseases of the eye, and the potential treatment solution that UNITY\u2019s lead program, UBX1325, may provide. Members of UNITY\u2019s senior management team and Key Opinion Leader Robert B. Bhisitkul, M.D., Ph.D., (University of California San Francisco School of &hellip; Continue reading &quot;UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-06T12:29:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTkzMyM1MTkwMTcxIzIwOTgyMjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye\",\"datePublished\":\"2022-10-06T12:29:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\\\/\"},\"wordCount\":326,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTkzMyM1MTkwMTcxIzIwOTgyMjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\\\/\",\"name\":\"UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTkzMyM1MTkwMTcxIzIwOTgyMjk=\",\"datePublished\":\"2022-10-06T12:29:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTkzMyM1MTkwMTcxIzIwOTgyMjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTkzMyM1MTkwMTcxIzIwOTgyMjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/","og_locale":"en_US","og_type":"article","og_title":"UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye - Market Newsdesk","og_description":"-Webinar to feature presentation from retinal expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 at 5:00 a.m. PT\/8:00 a.m. ET- SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an Investor\/Analyst Day on Wednesday, October 12, 2022 at 5:00 a.m. PT\/8:00 a.m. ET to discuss the current treatment landscape and unmet medical need for age-related diseases of the eye, and the potential treatment solution that UNITY\u2019s lead program, UBX1325, may provide. Members of UNITY\u2019s senior management team and Key Opinion Leader Robert B. Bhisitkul, M.D., Ph.D., (University of California San Francisco School of &hellip; Continue reading \"UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-06T12:29:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTkzMyM1MTkwMTcxIzIwOTgyMjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye","datePublished":"2022-10-06T12:29:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/"},"wordCount":326,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTkzMyM1MTkwMTcxIzIwOTgyMjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/","name":"UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTkzMyM1MTkwMTcxIzIwOTgyMjk=","datePublished":"2022-10-06T12:29:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTkzMyM1MTkwMTcxIzIwOTgyMjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTkzMyM1MTkwMTcxIzIwOTgyMjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-program-for-ubx1325-in-age-related-diseases-of-the-eye\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692831"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692831\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}